Lyra Therapeutics Inc LYRA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 9:20 AM EST
15.50quote price arrow up+0.58 (+3.89%)
Volume
861
Close
14.92UNCH (UNCH)
52 week range
8.76 - 22.00

...

Loading . . .

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close14.92
  • 52 Week High22.00
  • 52 Week High Date05/01/20
  • 52 Week Low8.76
  • 52 Week Low Date12/07/20
  • Market Cap192.92M
  • Shares Out12.93M
  • 10 Day Average Volume0.24M
  • Dividend-
  • Dividend Yield-
  • Beta
  • 1 Year % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-1.54
  • P/E (TTM)-9.69
  • Fwd P/E (NTM)-6.40
  • EBITDA (MRQ)-19.49M
  • ROE (MRQ)-
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Lyra Therapeutics Inc News

There is no recent news for this security.

Latest LYRA News From Our Partners

QUOTE FINDER

Profile

MORE
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases. The Company’s product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the...
Maria Palasis Ph.D.
President
R. Donald Elsey
Chief Financial Officer
Address
480 Arsenal St
Watertown, MA
02472-2891
United States